# Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)

> **NCT00481455** · PHASE2 · COMPLETED · sponsor: **CASI pharmaceuticals, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Glioblastoma Multiforme

## Interventions

- **DRUG:** Panzem NCD
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00481455
- **Lead sponsor:** CASI pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-09
- **Final completion:** 2008-10
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2008-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00481455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00481455, "Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00481455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*